Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.37 |
| ▸ | POLB | P06746 | 4/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 9/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.34 |
| ▸ | ATM | Q13315 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 8/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1637507 | 0.84 | CXCR4 (0.41) | — | |
| SCHEMBL1637977 | 0.84 | CXCR4 (0.41) | — | |
| SCHEMBL1638570 | 0.81 | CXCR4 (0.51) | MEN1KMT2APOLBNPSR1TDP1 | |
| SCHEMBL3737250 | 0.80 | CA1 (0.39) | MEN1KMT2APOLBNPSR1MAPT | |
| SCHEMBL1638545 | 0.78 | CXCR4 (0.42) | MEN1KMT2AATMMAPTKDM4E | |
| SCHEMBL1637535 | 0.78 | CXCR4 (0.42) | MEN1KMT2AATMMAPTKDM4E | |
| SCHEMBL1206908 | 0.74 | CXCR4 (0.46) | GLA | |
| SCHEMBL1637496 | 0.74 | CXCR4 (0.46) | GLA | |
| SCHEMBL1637376 | 0.74 | CXCR4 (0.46) | GLA | |
| SCHEMBL1636543 | 0.74 | CXCR4 (0.41) | MEN1KMT2AATMMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172212-A1 | AMINE-BASED COMPOUND AND USE THEREOF | KUREHA CORPORATION (JP) | 2011-07-14 | — | — | US | disclosed |
| US-7932281-B2 | Amine-based compound and use thereof | KUREHA CORPORATION (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20070208007-A1 | Amine-Based Compound and Use Thereof | KUREHA CORPORATION (JP) | 2007-09-06 | — | — | US | disclosed |
| EP-1724263-A1 | BASIC AMINE COMPOUND AND USE THEREOF | Kureha Corporation (JP) | 2006-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172212-A1 | AMINE-BASED COMPOUND AND USE THEREOF | NR0B2, NR5A2, NR1D2 | MEN1 1008/4885KMT2A 474/4885POLB 2350/4885 |
| US-20070208007-A1 | Amine-Based Compound and Use Thereof | NR0B2, NR5A2, NR2E1 | MEN1 1361/4885KMT2A 488/4885POLB 2259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.